Two registered RF patents. Nearly a decade of in-house R&D. Zero outsourcing.
Unlike conventional single-channel RF devices, NEWCHAE's patented multi-shot system distributes energy across multiple channels.
This means: higher efficacy at lower power levels, reducing the risk of surface discomfort while delivering energy uniformly to the target dermal layer.
Both patents issued by the Korean Intellectual Property Office and held by BRITZMEDI Co., Ltd.
BRITZMEDI operates its own R&D center, design studio, and manufacturing facility in Seongnam, Korea. Every NEWCHAE device is engineered, tested, and produced under ISO 13485:2016 quality management.
Concept, industrial design, and user experience mapping.
Circuit development, firmware, and mechanical integration.
Safety, reliability, and clinical validation protocols.
ISO 13485:2016 certified manufacturing facility.